DaVita HealthCare (DVA) closed higher than S&P 500, with positive growth expectations.

From Nasdaq: 2024-12-24 18:00:18

DaVita HealthCare (DVA) closed at $155.06, up +1.33% from the previous session, outpacing S&P 500’s 1.1% gain. Analysts anticipate an EPS of $2.21, 18.18% growth year-over-year, with revenue expected to reach $3.25 billion. The stock holds a Zacks Rank of #3 (Hold) and trades at a Forward P/E ratio of 15.76.

DaVita HealthCare is expected to post earnings of $9.71 per share for the full year, with revenue projected at $12.8 billion, marking changes of +14.64% and +5.45% from last year. The stock currently trades at a discount compared to its industry and has a PEG ratio of 0.86, reflecting strong potential for growth.

Investors can capitalize on positive estimate revisions for DaVita HealthCare by using the Zacks Rank system, which has a proven track record of exceeding expectations. The Medical – Outpatient and Home Healthcare industry, where DaVita operates, has a Zacks Industry Rank of 76, outperforming the bottom half of industries by 2 to 1. Stay updated on stock-impacting metrics through Zacks.com.

Zacks experts have identified 5 stocks set to double in 2024, with previous recommendations soaring as high as +673.0%. These under-the-radar picks offer an opportunity to invest early. Get the latest recommendations from Zacks Investment Research for potential home runs in the market.



Read more at Nasdaq: DaVita HealthCare (DVA) Laps the Stock Market: Here’s Why